Pharmaceutical giant Pfizer reported no major safety problems on their COVID-19 vaccine trial after more than 12,000 people received their second of two doses.
The vaccine showed promising results in developing antibodies that are seen in recovered patients. The U. S. government announced on Wednesday a whopping $1.
Read on to find out about the latest updates on some of the vaccines under trial against COVID-19. Based on a previous article, there are still many illnesses in the world where their vaccines are not yet discovered.
COVID-19 has resulted in a lot of economic and health constraints in the country. Pfizer aims to get a vaccine ready by fall to help get the country back on its feet.
In the past weeks, pharmaceutical and biotech companies have aimed to develop COVID-19 vaccines, which are now scheduled for human trials. Read on to find out how far each company has gone.
This 2015 has been the year of massive mergers and acquisitions, which set a new record at $5.03 trillion. According to Dealogic consultants, the annual total value for this year represented a substantial increase of 37 percent from 2015. While the last quarter of 2015 scored the highest figure for any quarter on record, Yahoo! News reported.
American companies that merge with smaller foreign firms in an effort to leave the nation's tax system should be charged an "exit tax," Democratic presidential front-runner Hillary Clinton said on Monday.
U.S. pharmaceutical giant Pfizer announced Monday that it would be combining with its Irish rival Allergan, forming the largest health care merger in the history of the industry.
The recent reports claiming that two big pharmaceutical companies, Pfizer and Allergan, are currently in talks of uniting has been confirmed. New reports say that the two healthcare giants might be announcing one of the biggest healthcare mergers on Monday.
Hobby Lobby, a craft store chain, won a groundbreaking and controversial case in the U.S. Supreme Court earlier this week regarding contraception coverage to its employees.
